新天藥業(002873.SZ)：現提議公司對參股公司匯倫生物進行增資8000萬元
格隆匯3月9日丨新天藥業(002873.SZ)公佈，公司董事會於2020年3月5日收到控股股東貴陽新天生物技術開發有限公司(“新天生物”，截至公告日，新天生物持有公司5156.8962萬股股票，佔公司總股本的44.04%)以書面形式送達的《關於提請貴陽新天藥業股份有限公司增加2020年第一次臨時股東大會臨時提案的函》，提議將《關於對參股公司增資暨關聯交易的議案》作為臨時提案提交公司2020年第一次臨時股東大會審議。
公司參股公司上海匯倫生物科技有限公司(原名“上海匯倫生命科技有限公司”，“匯倫生物”)的全資子公司上海匯倫江蘇藥業有限公司目前正在申報包括用於治療急性肺損傷/急性呼吸窘迫綜合徵的“注射用西維來司他鈉”等多個仿製藥及創新藥生產批件。為進一步加快公司在小分子化藥領域，包括抗腫瘤、心腦血管等疾病的仿製藥及創新藥領域的產業佈局，提請公司增加2020年第一次臨時股東大會臨時提案，將《關於對參股公司增資暨關聯交易的議案》作為臨時提案提交公司2020年第一次臨時股東大會審議。
公司於2020年1月15日召開第六屆董事會第十次會議，審議通過《關於對外投資暨關聯交易的議案》，同意公司以自有資金2000萬元人民幣對關聯方匯倫生物進行投資(增資完成後持股比例為1.98%)，2020年1月21日，公司與匯倫生物簽訂了《上海匯倫生命科技有限公司增資協議》並按照協議約定完成了投資，投資額為2000萬元。同時參與匯倫生物增資的其他主體分別為安徽中安9000萬元人民幣(增資完成後持股比例為8.91%)、眾泰宏倫3000萬元人民幣(增資完成後持股比例為2.97%)、雙福酒店2000萬元人民幣(增資完成後持股比例為1.98%)。以上投資主體均按照增資前匯倫生物評估基準日全部股東權益價值為8.5億元人民幣進行增資，增資完成後匯倫生物的全部股東權益價值為10.1億元人民幣。
現提議公司以自有資金對參股公司匯倫生物進行增資，增資金額為8000萬元人民幣。此次增資前對匯倫生物的價值確定為匯倫生物前次增資完成後的全部股東權益價值10.1億元人民幣，增資完成後，公司將持有匯倫生物9.1743%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
